Trial Profile
Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 16 Nov 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-000855-42).
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.